Clinicians should be aware of an increased risk for Fournier gangrene in patients with diabetes receiving sodium-glucose cotransporter 2 inhibitors.
Rachael BeairstoEditor https://www.dermatologyadvisor.com
Rachael Beairsto is a medical editor with Haymarket Media, Inc, overseeing all things related to hormone health at Endocrinology Advisor. She holds a BS in biology from Northeastern University in Boston, Massachusetts. Prior to joining Haymarket in 2018, Rachael worked at Ogilvy in a healthcare communications role and at Sanofi in a market research group supporting the marketing of established medications within the biosurgery and renal disease spaces.